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Abstract. Flaviviruses suchasZika, dengue, and yellow fever cause epidemics throughout the tropics andaccount for
substantial globalmorbidity andmortality. Althoughmalaria andother vector-borne diseases have longbeen appreciated
in Africa, flavivirus epidemiology is incompletely understood. Despite the existence of an effective vaccine, yellow fever
continues to cause outbreaks and deaths, including at least 42 fatalities in theDemocratic Republic of theCongo (DRC) in
2016. Here, we leveraged biospecimens collected as part of the nationally representative 2013–2014 Demographic
and Health Survey in the DRC to examine serological evidence of flavivirus infection or vaccination in children aged
6months to 5 years. Even in this young stratumof theCongolese population, we find evidence of infection by dengue and
Zika viruses basedon results fromenzyme-linked immunosorbent assay andneutralization assay. Surprisingly, therewas
remarkable discordance between reported yellow fever vaccination status and results of serological assays. The esti-
matedseroprevalencesof neutralizing antibodies against each virus are yellow fever, 6.0% (95%confidence interval [CI] =
4.6–7.5%); dengue, 0.4% (0.1–0.9%); and Zika, 0.1% (0.0–0.5%). These results merit targeted, prospective studies to
assess effectiveness of yellow fever vaccination programs, determine flavivirus seroprevalence across a broader age
range, and investigate how these emerging diseases contribute to the burden of acute febrile illness in the DRC.
INTRODUCTION
Arthropod-borne flaviviruses cause hundreds of millions of
infections in humans each year, with manifestations ranging
from fever to birth defects, hemorrhage, shock, encephalitis,
and even death. The public health importance of this group
of pathogens is immense and growing. Dengue virus (DENV)
has steadily expanded in both case number and geographi-
cal range over recent decades, leading to approximately
400 million infections annually.1 Zika virus (ZIKV) dramatically
emerged in Latin America in 2015, becoming an international
public health emergency because of the adverse fetal out-
comes that can occur when ZIKV is transmitted from an in-
fected mother to her developing fetus.2 Finally, yellow fever
virus (YFV) has caused hundreds of epidemics dating back to
at least the 17th century.3
Risk for transmission of all three of these viruses exists
wherever competent mosquito vectors, predominantly Aedes
aegypti, are found, andZIKVcanalsobesexually transmitted.4
The epidemiology of DENV and ZIKV in Asia and the Americas
is well described, but their epidemiology in Africa is in-
completely understood. Although there have been several
serosurveys for DENV and ZIKV in Africa, most of the studies
areoutdatedandconfoundedby theserological cross-reactivity
between flaviviruses.5,6 Infections in travelers returning from
Africa make up many of the more recent reports of DENV in
this region, hinting that prevalence in the African population is
likely largely underestimated.6 Similarly, reports of exported
ZIKV in travelers are common and these data are be-
ing leveraged to identify areas of endemicity, including in
Africa.7
On the other hand, the threat posed by YFV in Africa is well
recognized. A recent large outbreak in 2016 in Angola and
surrounding countries demonstrated that YFV represents a
constant hazard that can move quickly through susceptible
populations.8 Furthermore, despite the existence of an ef-
fective vaccine since the 1930s, substantial barriers remain to
successful implementation of this tool. Neglect of vaccination
programs, exacerbated by increasing, disorganized urbani-
zation in recent decades, has resulted in the resurgence of the
disease.9,10
The Democratic Republic of the Congo (DRC) is a large,
mostly rural country in central sub-Saharan Africa. Following
decades without reports of YFV transmission in the DRC, the
virus reemerged at the beginning of the 21st century, and at
least 42 deaths were confirmed in the country in 2016 alone
after the Angolan outbreak crossed country borders.11,12
These outbreaks occurred despite the YFV vaccine being
recommended by the Expanded Program on Immunization
since 2003.13
Because of the risk for YFV outbreaks in the DRC and
sparse data on other flavivirus infections such as DENV and
ZIKV, we conducted a seroepidemiological survey of these
three flaviviruses. We tested dried blood spots (DBSs) col-
lected from children during the 2013–2014Demographic and
Health Survey (DHS), a nation-wide, population representa-
tive survey, using both enzyme-linked immunosorbent assay
(ELISA) and neutralization assays to detect past flavivirus
exposure, analyzing the results in relation to geographi-
cal distribution and documented yellow fever vaccination
history.
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MATERIALS AND METHODS
Subjects and specimens. The DHS program (Rockville,
MD) employs household surveys and the collection of blood
samples to amass extensive, country-wide health and pop-
ulation data, including information about disease prevalence,
vaccination practices, nutrition, and beliefs and behaviors re-
lated to the spread of disease. All data and biospecimens are
collected with informed consent under Institutional Review
Board approval maintained by the Kinshasa School of Public
Health. In this study, we accessed de-identified archived DBSs,
whichwerecollectedbetween2013and2014during thesecond
DHS in the DRC. Each DBS was spotted with approximately
45 μL of blood collected from participants in their homes during
the survey.14 From 9,790 DBSs collected from children aged
6 months to 5 years in representative household clusters, 10%
(978) were randomly selected for inclusion in the present study.
Elution of blood from DBSs. Eluted sera and DBSs were
stored at −80C until use. Sera were stored in sealed 96-well
plates and DBSs in sealed plastic bags with desiccant. For initial
ELISAs,archivedelutedserawereused.One6-mmholepunchof
each DBS was previously eluted in 1 mL phosphate-buffered
saline, 0.05% w/v Tween 20%, and 5% w/v nonfat dried milk
powder, with elution by shaking for 1 hour at room temperature.
For neutralization assays, DBSs were freshly eluted in Dul-
becco’s modified Eagle medium (DMEM, Gibco, 11330-032)
supplementedwith 2% fetal bovine serum (Millipore, TM-013-
B), 1% L-Glut (Gibco, 25030-081), 1% Anti-Anti (Gibco,
15240-062), and 1% non-essential amino acids solution
(Gibco, 11140-50) at a concentration of 1:20 (one 6-mm hole
punch of dried blood per 150 μLmedium). Sera were eluted by
rocking for 2 hours at 37Cand then centrifuged to remove the
supernatant from the pelleted filter paper. The sera were heat
inactivated for 30 minutes in a 56Cwater bath. The samples
were centrifuged again to pellet proteinaceous debris and
only the supernatant was transferred to a final tube. The
eluted sera were stored at 4C and tested within 3 days.
Virus strains. The following World Health Organization
(WHO) reference strains of viruses were used: DENV1, West
Pac 74; DENV2, S-16803; DENV3, CH-54389; DENV4, TVP-
360; ZIKV, H/PF2013; and YFV, 17D.
ELISA.Asdescribed previously, each of the serum samples
was tested for flavivirus-binding antibodies in three sepa-
rate immunoglobulin G (IgG) antigen-capture ELISAs to the
following antigens:DENVserotypes 1–4mix, ZIKV, andYFV.15
ELISA plates were coated overnight at 4C with 100 ng of the
mousemAb 4G2 (ATCC, HB-112). Eachwell waswashedwith
tris-buffered saline containing 0.2% v/v Tween and then
blocked for 2hours at 37Cwithblockingbuffer containing3%
w/v nonfat dry milk. Viral antigens were captured for 1 hour at
37CandELISAplateswerewashed. Fiftymicroliters of eluted
serawere added in singlicate to the ELISAplate and incubated
for 1 hour at 37C. The plates were washed and alkaline
phosphatase–conjugatedgoat antihuman IgG (A9544; Sigma,
St. Louis,MO)was added and incubated for an additional hour
at 37C and then washed again before the addition of
p-nitrophenyl phosphate substrate. Absorbance was mea-
sured at 405 nm on an Epoch microplate spectrophotometer.
Readings were taken every 5 minutes for 25 minutes. A posi-
tive control (serum from an individual with known previous
exposure to the virus) and normal human serum (NHS) negative
control were included in duplicate on each plate. The last plate
reading at which the difference between the positive control
optical density (OD) andnegative control ODwas less than 1.5
(DENV and ZIKV) or less than 0.5 (YFV) was analyzed. Be-
cause the NHS control often exhibited higher background
thanmany of the test samples, the background signal for each
plate was defined as the average of the eight lowest ODs from
the test samples on the plate. The threshold OD for positives
was defined as themeanof the eight lowestODs+ 3 standard
deviations + 0.1 (DENV and ZIKV) or + 0.05 (YFV).16,17 The
correction factor of 0.1was reduced to 0.05 for theYFVassay
because theODvalueexhibitedby thepositive control and the
general distribution of OD values on each plate were consis-
tently approximately 50% of those in the DENV assay.
Micro-neutralization assay. A standard focus reduction
neutralization test (FRNT) was modified to accommodate
limited specimen availability.15 Briefly, four serial 3-fold dilu-
tions were made of each serum sample and mixed with equal
volume of virus at a concentration of ∼40–140 focus-forming
units, incubated for 1 hour at 37C, and then transferred to
96-well plates seeded with Vero-81 cells. After 1 hour, overlay
medium was added and the infected cells were incubated
for 40 hours (ZIKV), 48 hours (DENV2 and DENV4), or 51–52
hours (DENV1, DENV3, and YFV) at 37C. The cells were fixed
with 4% paraformaldehyde for 30 minutes and then per-
meabilization buffer was added for 10 minutes followed by
blocking buffer (3% normal goat serum) and left overnight at
4C.Amixture of primary antibodies 4G2 and2H2 (ATCC,HB-
114) were added to the plates and incubated for 1 hour at
37C. The cells were washed followed by the addition of goat
antimouse secondary antibody conjugated with horseradish
peroxidase (Kirkegaard and Perry Laboratories, 074-1806) for
1 hour at 37C. The plates were washed again and then foci
were stained with TrueBlue (Kirkegaard and Perry Labora-
tories, 5510-0030) and counted. Two NHS controls were
included on every plate to define 100% infection. Sera
with > 50%neutralization at the first dilution point were further
analyzed in Prism 7 (GraphPad, La Jolla, CA, www.graphpad.
com). Focus reduction neutralization test 50 values (the serum
dilution effecting a 50% reduction in virus infection) were de-
termined by a nonlinear regression model using the sigmoidal
dose response (variable slope) equation. Because of some
nonspecific inhibition of infection by many ELISA-negative
samples and negative controls, an FRNT50 < 100 was con-
sidered background and sera with FRNT50 > 100 were con-
sidered positive for neutralizing antibodies.
Data visualization and mapping. Euler diagrams were
constructed using EulerAPE v3.0 and Venn diagrams using
BioVenn.18,19 Episheet was used to calculate exact confidence
intervals (CIs).20 Samples were linked to their geographical
location using theDRC2013–2014Global Positioning System
dataset from the DHS, and ArcGIS 10.4 was used to map the
data and examine spatial patterns.
RESULTS
All 978 serumsampleswere testedbyELISAanda subset of
ELISA-positive and ELISA-negative sera were tested by neu-
tralization assay (stratified by virus, Figure 1; across all viruses
tested, Supplemental Figure 1).
Of the 978 sera tested, 183 (18.7%) were positive for
binding antibodies to one or more of the three flaviviruses
tested. One hundred and sixty-seven (17.1%) reacted with
YFV, 34 (3.5%) with ZIKV, and 37 (3.8%) with DENV. Of the
ELISA-positive samples, 43 (23.5%) had antibodies that
reacted with more than one of the viruses tested (Figure 2),
which could be due to antibody cross-reactivity among
flaviviruses or prior infection by or vaccination against more
than one virus. The numbers (and percent of total ELISA-
positive specimens) uniquely positive for YFV, DENV, or ZIKV
were 129 (70.5%), five (2.7%), and six (3.3%), respectively.
To address the risk of false-positive ELISA results due to
cross-reactive antibodies, we tested samples froma subset of
subjects for the presence of neutralizing antibodies.21 Sub-
jects were selected for neutralization testing based on sample
availability, initial ELISA results, and YFV vaccine status, with
the goal of testing both ELISA-positive and ELISA-negative
and YFV-vaccinated and YFV-unvaccinated subjects. Of
note, sera were not randomly selected for YFV neutralization
testing; rather, sera with the most remaining sample and/or
highest ELISA ODs were preferentially tested. Because sam-
ple volume was limiting, a modified FRNT approach was used
(see Materials and Methods).22
Few sampleswere neutralization positive for ZIKV or DENV
(Figure 1 and Table 1). Of 32 DENV ELISA-positive sera
tested by neutralization assay, three (9.4%) were positive for
neutralizing antibodies against DENV; of 21 DENV ELISA-
negative sera tested, none were positive for neutralizing
antibodies against DENV; of 31 ZIKV ELISA-positive sera
tested, one (3.2%) was positive for neutralizing antibodies
against ZIKV; and of 33 ZIKV ELISA-negative sera tested,
none were positive for neutralizing antibodies against ZIKV
(Figure 1).
One of the specimens exhibited neutralization against
DENV1, DENV2, and DENV3. This is likely due to two or more
past DENV infections or cross-neutralizing antibodies from a
recent primary infection.17 A second specimen neutralized
DENV2andYFV, anda third neutralized onlyDENV1. TheZIKV
neutralization-positivespecimendidnotexhibit cross-neutralizing
antibodies (Table 1).
FIGURE 1. Enzyme-linked immunosorbent assay (ELISA) and neutralization testing flowchart. Of the total study population of 978 samples, the
breakdown by ELISA positivity, selection for neutralization testing, and neutralization results are shown. Percentages of positive samples out of the
total number tested using each assay are shown in parentheses. Results are stratified by virus.
FIGURE 2. Distribution of sera with cross-reactive binding anti-
bodiesagainst denguevirus (DENV), Zika virus (ZIKV), andyellow fever
virus (YFV). The number of sera positive by enzyme-linked immuno-
sorbent assay (ELISA) for IgG against each virus is shown (DENV =
pink, ZIKV = green, and YFV = transparent). Sera with reactive anti-
bodies against two or three viruses are shown in the overlapping
areas. The number of children negative by ELISA against all three
viruses is shown in the bottom left. Each number refers to a distinct
section, for example, 129 sera were uniquely positive for anti-YFV
antibodies and15sera hadantibodiesagainst bothYFVandDENVbut
not ZIKV. This figure appears in color at www.ajtmh.org.
More subjectswere positive for YFV-neutralizing antibodies
(Figure 1). Of 92 YFV ELISA-positive and 139 ELISA-negative
sera testedby neutralization assay, 29 (31.5%) andone (0.7%)
were positive for neutralizing antibodies against YFV, re-
spectively. The single YFV ELISA-negative subject with de-
tectable neutralizing antibodies reported a history of YFV
vaccination.
Based on the number of subjects with neutralizing anti-
bodies in each subset of ELISA-positive and ELISA-negative
sera tested for each virus, we can approximate the seropre-
valences in thewhole cohort to be as follows: YFV, 6.0% (95%
CI = 4.6–7.5%); DENV, 0.4% (0.1–0.9%); and ZIKV, 0.1%
(0.0–0.5%).
Overall, YFV ELISA and neutralization results correlated
poorly with reported vaccination history (Figure 3). Among
the 705 subjects with known vaccination history, 418 re-
ported receiving YFV vaccination but only 77 of these
(18.4%) were positive by ELISA (Figure 3A). In the subset of
178 sera from children with known vaccination history that
also underwent neutralization testing, 134 received vacci-
nation, but only 20 of these (14.9%) had neutralizing anti-
bodies (Figure 3B). Similar proportions of YFV-unvaccinated
individuals were found to be ELISA positive (34 of 287,
11.8%; Figure 3A) and have neutralizing antibodies (6 of 44,
13.6%; Figure 3B). Of note, 29 of 30 (96.7%) of specimens
testing positive for YFV neutralization antibodies were also
ELISA positive, which lends credence to the laboratory
methods used here (Figure 3C).
To confirm the discordance between reported vaccination
and YFV serology results, we compared the FRNT50 values
of 110 sera tested by neutralization assay from children who
either had vaccine cards that confirmed YFV vaccine admin-
istration or reported not receiving the vaccine. This excludes
children whose mothers affirmed YFV vaccination history
status but lacked vaccine cards so as to minimize the impact
of recall bias on our findings. There was no difference in the
distributions of FRNT50 values between the two groups
(Mann–Whitney test, P = 0.3107; Supplemental Figure 2).
Results from both the ELISA and neutralization assay were
spatially mapped by DHS sampling location to visualize the
geographical distribution of flavivirus seropositivity across the
DRC. There was no spatial clustering of ELISA-positive sam-
ples (Figure 4A). Samples with neutralizing antibodies against
any of the three flaviviruses were observed more frequently
near the border regions of the country (Figure 4B), although
there was no significant spatial clustering according to the
Moran’s I test of spatial autocorrelation. In addition, the lo-
cations of childrenwho tested positive for yellow fever binding
or neutralizing antibodieswere comparedwith the locations of
yellow fever outbreaks reported by WHO in the 5 years pre-
ceding the DHS (Figure 4C).23 There was no clear spatial re-
lationship between yellow fever–positive samples and known
yellow fever outbreaks; however, clusters of children with
neutralizing antibodies against yellow fever are seen along the
border with Rwanda and near the capital city of Kinshasa.
These clusters could be sites of undetected outbreaks,
Sample ID ELISA positive Neutralization positive Neutralization negative
223 DENV, ZIKV, and YFV DENV1, DENV2, and DENV3 DENV4
2759 DENV and ZIKV DENV1 DENV2–4, ZIKV, and YFV
7787 DENV, ZIKV, and YFV DENV2 and YFV DENV1, 3, and 4 and ZIKV
4787 ZIKV ZIKV YFV
ELISA = enzyme-linked immunosorbent assay; DENV = dengue virus; YFV = yellow fever virus; ZIKV = Zika virus.
FIGURE 3. Overlap between yellow fever virus enzyme-linked immunosorbent assay (ELISA) results, neutralization assay results, and reported
vaccination status. The number of childrenwith each condition or combination of conditions is shown in the corresponding section (reported yellow
fever vaccination = gray, ELISA positivity = green, and neutralizing antibodies = blue). The number of children negative for all conditions is shown in
the bottom left of each panel. (A) Yellow fever vaccination history vs. ELISA positivity and includes all children with known vaccination history. (B)
Yellow fever vaccination history vs. neutralization testing results and includes all children with both known vaccination history and neutralization
testing results. (C) ELISA positivity vs. neutralization assay results and includes all children with neutralization testing results. This figure appears in
color at www.ajtmh.org.
TABLE 1
Sera positive for DENV- or ZIKV-neutralizing antibodies
represent areas with higher vaccine coverage, or higher se-
roconversion following vaccination.
DISCUSSION
This study provides evidence that flaviviruses, including
DENV, ZIKV, and YFV are circulating in the DRC and suggests
a lack of seroconversion in many Congolese children with
histories of vaccination against YFV. To our knowledge, this
study presents the first evidence of ZIKV in the DRC. Neu-
tralizing antibodies against ZIKVwere only reported in a single
sample, and this sample was not tested by neutralization as-
say against YFV and DENV (although it failed to react to these
viruses when tested by ELISA); therefore, this finding remains
inconclusive and should be confirmed in future studies. Our
data confirm previous reports that DENV is present in the DRC
at a prevalence < 1% in children younger than 5 years. The
prevalence of malaria parasites reported in the same age
range is around 38%, suggesting that malaria continues to be
a more common cause of febrile illness in the DRC.24
The detection of antibodies against ZIKV is not surprising,
given that the virus was originally isolated in Uganda and has
been reported in many countries bordering the DRC.5 Dengue
virus was known to have a presence in the DRC based on
sporadic detection of virus or antibodies in the Congolese
population, returning travelers, and wild game animals.6,25,26
Our data further indicate that DENV serotypes 1 and 2 are co-
circulating and suggest the virus is not localized to any one
area of the country. In dengue-hyperendemic areas of Asia
and Latin America, seroprevalence in children younger than 5
years ranges from 34% to 60%, and well over half of children
have been exposed by age 10.16,27–29 Although few data are
available for ZIKV seroprevalence in other countries in this age
group, we can reasonably assume that children living in urban
areas of Latin America and Asia where ZIKV has recently
emerged have had ample opportunity for infection. Seropre-
valence among schoolchildren aged 6–16 years was 66% in
an area of French Polynesia in 2014–2015.30 In Bolivia, where
the virus arrived as recently as 2016, seroprevalence in adults
in some regions already reaches around 20–40%.31 We hy-
pothesize that DENV and ZIKV infections in the DRC are likely
sporadic spillover events, a distinct ecology from the urban
cycle that drives high transmission of these viruses in other
countries. If so, children would have little opportunity for ex-
posure, but seroprevalence may be significantly higher in
other population subgroups (e.g., men working near heavily
forested areas who are at risk of exposure to the sylvatic cy-
cle). A better understanding of flavivirus epidemiology in
countries such as the DRC is needed to optimize surveillance,
identify populations most at risk, and improve diagnosis and
treatment of non-malarial febrile illness. More generally, the
myriad etiologies of acute febrile illness in developing coun-
tries is increasingly appreciated, and enhanced detection of
flaviviruses will ideally be but one component of a greater ef-
fort to improve diagnostic laboratory capacity.32
For all three flaviviruses tested, therewere a large number of
sera positive by ELISA but negative by neutralization assay.
This raises the possibility that other closely related flavivi-
ruses are present in the DRC. A recent study detected flavi-
virus nucleic acids, but not DENV or YFV, in mosquitoes in
Kinshasa.33 At least 10 other flaviviruses have been reported
in Africa.34 This combined with the results reported here
suggests that the diversity of flaviviruses circulating in the
DRC may be underappreciated. In addition, infection with
malaria can also cause false-positive serologic test results for
a number of pathogens as recently reiterated in reports of
false-positive ZIKV testing with malaria infection.35,36
Maternal antibodies in the sera of the youngest subjects in
this studymay explain a small proportion of the positive ELISA
and neutralization results. Anti-DENV maternal antibodies
begin to decay substantially by 6 months of age and com-
pletely disappear inmost childrenby12months.37–39Previous
studies have reported that maternal antibodies fall to sub-
neutralizing levels during their decay and potentially become
disease enhancing.40,41 The presence of binding, non-
neutralizingmaternal antibodiesmay explain someof the lack
of correlation between the ELISA and neutralization results
reported here.
FIGURE4. Geographical distributionof samples andserology testing results. Eachpoint on themap representsaDemographic andHealthSurvey
sampling cluster; clusters with no children testing positive are transparent. (A) Sampling clusters with children positive by enzyme-linked immu-
nosorbent assay (ELISA) for antibodies against dengue virus (DENV), Zika virus (ZIKV), and/or yellow fever virus (YFV). (B) Sampling clusters with
children positive for neutralizing antibodies against each of the three viruses. (C) Sampling clusterswith children positive for antibodies against YFV
byELISAandneutralizationassayoverlaidon locationsof knownYFVoutbreaksas reportedby theWorldHealthOrganization.61 Thisfigureappears
in color at www.ajtmh.org.
A striking finding of our study was the discovery that most
children reported to have received the YFV vaccine failed to
show evidence of seroconversion. This finding held true even
when only children with vaccine cards were included in the
analysis (i.e., excluding children whose vaccine history is only
verbally reported by their mothers without a vaccine card),
making misreporting an unlikely explanation. This phenome-
non is worrisome and without precedent in the literature. The
YFV vaccine is highly immunogenic, and both the WHO and
the U.S. Centers for Disease Control and Prevention recently
concluded that a single dose of the vaccine is sufficient for
lifelong immunity inmost populations, although this statement
is not universally accepted.42–48 There is some evidence that
children are less likely to seroconvert than adults; however,
the rates of seroconversion in children are nevertheless con-
sistently reported to be above 80%.44,49–51
Duration of immunity in children receiving the YFV vaccine
must also be considered in addition to early convalescent se-
roconversion; but unfortunately, data to that point are notably
deficient in the literature over the past half century. Moreover, it
has been suggested that a proportion of children lose seropos-
itivity following vaccination, which could be consistent with our
findings.42,45,49 However, the very low seroconversion rate ob-
served in the present study may not be entirely attributable to
the youngageof vaccinees. A secondpossible explanation is
that coadministration of the YFV vaccine with another live-
virus vaccine is contributing to lower seroconversion. Sev-
eral studies have investigated decreased immunogenicity of
the YFV vaccine because of interference by coadministration
of the measles vaccine, with conflicting results.52–55 Nota-
bly, the vast majority of children in the present study who had
dated vaccination cards received the YFV vaccine on the
same day as the measles vaccine.
The high prevalence of malnutrition in children in the DRC
could also be contributing to impaired immune responses to
the vaccine. In the 2013–2014DHS, 43%of children surveyed
were chronically malnourished.56 Malnutrition has been re-
ported to variably diminish antibody production following a
number of vaccinations, and studies in the 1960s specifically
detected an impaired immune response to the YFV vaccine in
children with protein malnutrition.57–59
It is also possible that the sensitivity of the ELISA and neu-
tralization assays performed in this study were insufficient to
detect low levels of antibodies that are sufficient for protection,
although the vaccine is generally thought to evoke high neu-
tralizing antibody titers, well over the limits of detection of the
assays used in the present study.60 It should be noted that there
is no established correlate of protection against yellow fever in
humans; therefore, neither an ELISA nor a neutralization assay
can definitively indicate who is and is not immune to disease
caused by yellow fever infection following vaccination.42
The fact that the DRC continues to experience major yellow
fever outbreaks indicates that a substantial portion of the
Congolese population remains susceptible to infection de-
spite renewed efforts to integrate the YFV vaccine into routine
childhood vaccination programs.12 The issuewith the vaccine
may be as much programmatic as biological, that is, due to
difficulties in accessing remote areas, poor surveillance, and/
orsuboptimal transport andstorageof thevaccine.Prospective
studies to evaluate seroconversion following vaccination and
monitor for vaccine failures could bolster public health initia-
tives to protect the Congolese population from yellow fever.
Strengths of this study include the use of specimens
from a nationally representative survey, which allowed for the
estimation of country-wide prevalence and access to geo-
graphic location and vaccine history linked to each sample.
The study was limited by sample availability, which only
allowed for testing samples in singlicate and prohibited
neutralization testing of some ELISA-positive sera; selec-
tion bias in which sera were tested by neutralization assay;
recall bias in reporting vaccination history; testing of a single
age group; and potentially low sensitivity of the YFV ELISA
assay based on modest OD values exhibited by the positive
controls.
Overall, the results presented here suggest that flavivirus
epidemiology in the DRC and throughout Africa warrants fur-
ther study. Additional research is required to corroborate and
investigate the reasons for the low rates of seroconversion
observed in vaccinated Congolese children. Moreover, future
surveillance undertakings should investigate flavivirus sero-
prevalence across a larger population of all ages. Distinct
studies should explore flavivirus infection as an etiology of
acute febrile illness, especially in patientswho test negative for
malaria. These combined activities will characterize the health
burden of flavivirus infections in the DRC and improve
standard practices for their diagnosis and treatment. This
type of study would also facilitate the isolation, sequencing,
and phylotyping of wild-type virus, which would improve
knowledge of the history and evolution of these viruses on
the African continent. Ultimately, a better understanding of
global flavivirus epidemiology will also help to identify pop-
ulations at highest risk for these pathogens with epidemic
potential and provide early opportunities for their detection
and prevention.
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Publique, Faculté de Médecine, University of Kinshasa, Kinshasa,
Democratic Republic of the Congo, E-mails: mwandaga@email.unc.
edu and antotshe@yahoo.com. Steven R. Meshnick, Department of
Epidemiology, Gillings School of Global Public Health, University of
North Carolina, Chapel Hill, NC, E-mail: meshnick@unc.edu.
REFERENCES
1. Guzman MG, Harris E, 2015. Dengue. Lancet 385: 453–465.
2. Krauer F, Riesen M, Reveiz L, Oladapo OT, Martı́nez-Vega R,
Porgo TV, Haefliger A, Broutet NJ, Low N; WHO Zika Causality
Working Group, 2017. Zika virus infection as a cause of con-
genital brain abnormalities and Guillain–Barré Syndrome: sys-
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